Fucoidan is a sulfated polysaccharide extracted from brown seaweed. It has been demonstrated that fucoidan exhibits anti-tumor, anti-allergic, anti-coagulate, anti-microbial, anti-viral, and anti-parasitological effects of fucoidan.
Recently, we reported that (i) Mekabu fucoidan (meFucoidan) purified from the 0.15 N HCl extract of Undaria pinnatifida sporophylls highly induces an activation of the Th1 cell immune reaction, and effectively suppresses the Th2 cell immune reaction in animal models 1, 2) ; and (ii) the ester sulfate of meFucoidan is an active site to prevent the adhesion of Cryptosporidium parvum to the intestinal epithelial cells. 6) However, the direct physiological interaction of meFucoidan with the mediating factors involved in these meFucoidan-induced biological effects remain to be elucidated.
Secretory group IIA phospholipase A 2 (sPLA 2 -IIA) catalyzes the hydrolysis of the sn-2 fatty acyl ester bond of phospholipids to yield a free fatty acid, very often arachidonic acid, and a lysophospholipid. 7) sPLA 2 -IIA is highly expressed in several types of mammalian cells and tissues, and this enzyme acts as a critical modulator of cytokine-mediated synovial inflammatory diseases, 8) rheumatoid arthritis 9, 10) and neoplastic disease.
11) Therefore, it is an interesting to examine the direct interaction of meFucoidan with sPLA 2 -IIA in vitro, since sPLA 2 -IIA is known to be an important virulence factor for a wide range of parasites and also one of functional mediators for parasitic disruption. 12) On the other hand, we reported recently that (i) two sulfated lipids [sulfatide and cholesterol-3-sulfate (CH-3S), SCS] highly stimulate the phosphorylation of several SCSbinding proteins (SCS-BPs), such as high mobility group protein 1 (HMG1), 13) bovine FGF-binding protein (FGF-BP), 14) and p5 (N-terminal 28 amino acid residues of acidic FGF-BP), 15) by casein kinase 1 (CK1) in vitro; and (ii) the direct binding of SCS to these basic proteins causes them to undergo conformational changes, which presumably facilitate their high phosphorylation by CK1 in vitro. [13] [14] [15] However, there is no report concerning the effect of meFucoidan on the physiological functions of these SCS-BPs involved in the inflammatory responses. Therefore, the present study was carried out to determine (i) the inhibitory effect of meFucoidan, in comparison with two sulfated compounds (heparin and sulfatide), on the activities of sPLA 2 -IIA and pancreatic PLA 2 (pPLA 2 ); (ii) the binding affinity of meFucoidan with four functional basic proteins (sPLA 2 -IIA, bFGF, histone H2B and Hcore 164B) and four synthetic FGF-BP peptides (sp5, GE13, RS6 and RS6 variant) containing potent phosphorylation sites for cAMP-dependent protein kinase (A-kinase); and (iii) the inhibitory effect of meFucoidan on the A-kinase-mediated phosphorylation of these substrate peptides in vitro. Preparation of meFucoidan Milled mekabu (sporophyll of Undaria pinnatifida) was prepared, as described in our previous reports. 1, 2) After the non-dialyzable portion was evaporated and lyophilized, the crude fucoidan extract was ultrafiltrated through a membrane filter ACP-013 (MW 13000; Asahi Kasei Co., Ltd., Tokyo, Japan). Fucoidan in the filtrate fraction was partially purified by ion-exchage column chromatographies, as originally described by Lee et al. 5) The partially purified fucoidan fraction (meFucoidan) used in the present study was composed of 32.2% ester sulfate, as reported previously. 6) Assay for the Activities of Two PLA 2 s in Vitro The activity of sPLA 2 -IIA or pPLA 2 (approx. 2 mg each) was measured, using NBD-PE (Avanti Polar-lipid, Inc.) as a substrate, as reported previously. 16) Reaction mixtures (total 100 ml) comprising 50 mM Tris-HCl (pH 8.0), 123 mM NBD-PE, 2 mM Ca 2ϩ and the indicated mounts of sPLA 2 -IIA or pPLA 2 were incubated for 30 min at 30°C in the presence or absence of the indicated concentrations of meFucoidan or two sulfated compounds (sulfatide and heparin).
Characterization of meFucoidan as a Selective Inhibitor for Secretory

Measurement of the Binding-Affinities of meFucoidan with Five Basic Proteins and Four Synthetic Peptides
Using a QCM The binding affinities of meFucoidan with five basic proteins (sPLA 2 -IIA, pPLA 2 , bFGF, histone H2B and Hcore 164B) and four synthetic FGF-BP peptides (sp5, GE13, RS6 and RS6 variant) were separately measured, using a quartz crystal microbalance (QCM, Initium, Tokyo, Japan), as described in our previous reports. 14, 15) Briefly, these functional basic proteins and synthetic peptides were separately immobilized on a QCM plate in 8 ml of 40 mM Tris-HCl (pH 7.2) at 30°C until an equilibrium was attained. The indicated concentrations of meFucoidan were added to the equilibrated solutions. The frequency changes in the QCM responding to five basic proteins and three synthetic peptides with meFucoidan were recorded for specific time points. The stability of the 27-MHz QCM frequency in the solution was 5 Hz for 12 hrs at 30°C.
Assay for the Inhibitory Effect of meFucoidan on the Phosphorylation of Four Distinct Substrates by A-Kinase in Vitro
The A-kinase standard reaction mixtures (50 ml) comprised 50 mM Tris-HCl (pH 7.6), 3 mM Mn 2ϩ , 2 mM DTT, 1 mM cAMP, A-kinase (approx. 1 unit), 5 mM [g-32 P]ATP (500 cpm/pmol) and the indicated substrates (bFGF, histone H2B, Hcore 164B or GE-13, approx. 2 mg each). The reaction mixtures were incubated for the indicated periods at 30°C in the presence or absence of meFucoidan. The phosphorylation of these four substrates by A-kinase was arrested by the addition of SDS-PAGE sample buffer, as described in our previous reports.
14,15) 32 P-Labeled substrates in the reaction mixtures were detected by autoradiography after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Densitometric analysis of scanned autoradiogram images was performed using (an NIH public domain image program) on a Macintosh computer.
RESULTS AND DISCUSSION
The inhibitory effects of three sulfated compounds (meFucoidan, heparin and sulfatide) on the activities of sPLA 2 -IIA and pPLA 2 were comparatively determined in vitro. As shown in Fig. 1A , meFucoidan highly inhibited the activity of sPLA 2 -IIA, but not pPLA 2 , whereas both enzyme activities were highly stimulated by sulfatide. Under the same experimental conditions, no significant effect of heparin (100 mg/ml) on the activities of two PLA 2 s (sPLA 2 -IIA and pPLA 2 ) was observed (Fig. 1A) . Furthermore, meFucoidan inhibited dose-dependently sPLA 2 -IIA activity with 50% inhibition (ID 50 ) at approx. 45 mg/ml, whereas this compound at 100 mg/ml reduced about 6% of pPLA 2 activity (Fig. 1B) . [A] The activity of sPLA 2 -IIA or pPLA 2 was measured, using NBD-PE as a substrate. Reaction mixtures (total 100 ml) comprising 20 mM Tris-HCl (pH 8.0), 123 mM NBD-PE, 2 mM Ca 2ϩ and sPLA 2 -IIA or pPLA 2 (approx. 2 mg each) were incubated for 30 min at 30°C in the presence or absence of 100 mg/ml meFucoidan, 100 mg/ml heparin or 100 mM sulfatide. The rate 1 represents the activity of sPLA 2 In addition, the physiological interaction of meFucoidan with two PLA 2 s was determined by a QCM, which is a useful quantitative technique to directly detect the molecular frequency changes in these two enzymes or meFucoidan-binding polypeptides at the nanogram level. As shown in Fig. 1C , meFucoidan directly bound to sPLA 2 -IIA (pIϭapprox. 9.4), but not pPLA 2 (pIϭapprox. 6.3). The discrepancy of these two PLA 2 s may be due to the high content of basic amino acids [Lys (K)/Arg (R)-rich domain] of sPLA 2 -IIA, which has the property distinguishable form that of pPLA 2 . From these results presented here and the biochemical properties of sPLA 2 -IIA, it was concluded that (i) meFucoidan acted as a selective inhibitor for sPLA 2 -IIA through its direct binding to the K/R-rich domain of the enzyme; and (ii) the meFucoidan-induced inhibition of sPLA 2 -IIA activity was different from the effects of other two sulfated compounds (heparin and sulfatide) on the enzyme activity in vitro.
To determine the meFucoidan-binding sites in several functional basic proteins, which act as effective phosphate acceptors for A-kinase, basic FGF (bFGF, pIϭapprox. 9.6) and three synthetic FGF-BP peptides (sp5, GE13 and RS6), containing a potent phosphorylation site (B-B-X-S/T, where B is a basic amino acid and X is a hydrophobic residue) for A-kinase, were prepared. As shown in Fig. 2A , it was confirmed that (i) meFucoidan directly bound to bFGF and three synthetic peptides (sp5, GE13 and RS6); (ii) meFucoidan had a higher binding affinity with GE13, as compared with the others (sp5 and RS6); and (iii) the binding affinity of meFucoidan with RS6 (a minimum peptide recognized by A-kinase) was higher than that of RS6 variant. As expected, meFucoidan inhibited dose-dependently the A-kinase-mediated phosphorylation of two substrates (bFGF and GE13) with similar kinetics (Fig. 2B) . Under the same experimental conditions, meFucoidan at a lower concentration (ID 50 ϭapprox. 0.7 mg/ml) inhibited the A-kinase-mediated phosphorylation of RS6 (Fig. 2B) . In contrast, the phosphorylation of sp5 by A-kinase required to inhibit a relative high concentration (ID 50 ϭapprox. 5 mg/ml) of meFuciodan, since sp5, in comparison with GE13, had a lower binding affinity with meFucoidan ( Fig. 2A) . These results show that two K/R-rich domains (B-B-B-B-X and B-X-B-B-X), which are partially overlapping to the potent phosphorylation site (B-B-X-S/T) for A-kinase in these three polypeptides (bFGF, sp5 and GE-13), may be responsible for the binding of meFucoidan in vitro. Although sPLA 2 -IIA has not a potent phosphorylation site for A-kinase, sPLA 2 -II, but not pPLA 2 , contains a K/Rrich domain (B-B-X-X-B-B), which may be responsible for the binding of meFucoidan in vitro.
Recently, we reported that (i) an activated A-kinase highly phosphorylated Ser-residues (positions at 155, 162 and 170 in the strain ayw) of three adjacent SPRRR repeats in an Arg (R)-rich C-terminal region of hepatitis B virus (HBV) core protein [HBV-CP, 21 kDa phosphoprotein (185 amino acid residues)] in vitro 7) ; and (ii) this phosphorylation is selectively inhibited by suramin (a sulfated compound) through its directly binding to the R-rich C-terminal region on HBV-CP. 18 ) Therefore, the in vitro assay was designated to identify the potent meFucoidan-binding domains on two basic proteins [Hcore 164B (22 amino acid residues, pIϭapprox. 12.3) and histone H2B (126 amino acid residues, pIϭ10.3)], which function as effective phosphate acceptors for A-kinase in vitro. 7) As shown in Fig. 3B , it was found that (i) meFucoidan inhibited the A-kinase-mediated phosphorylation of histone H2B in a dose-dependent manner from 0.1 to 30 mg/ml; and (ii) meFucoidan highly inhibited the A-kinasemediated phosphorylation of Hcore 164B with an ID 50 ϭap-prox. 0.2 mg/ml, which are about 25-hold lower than that (ID 50 ϭapprox. 5 mg/ml) of heparin. In addition, meFucoidan, in comparison with heparin, had the higher binding affinities with histone H2B and poly-Arg (Fig. 3C ), but there are no potent meFucoidan-binding domains in the catalytic and regulatory subunits of A-kinase. These results suggest that meFucoidan functions as an effective inhibitor for the A-kinasemediated phosphorylation of two meFucoidan-binding basic proteins (histone H2B and Hcore 164B) through its direct binding to these two substrates in vitro.
In comparison with the amino acid sequences, containing phosphorylation sites for A-kinase, in four basic polypeptides (histone H2B, Hcore 164B, bFGF and GE13), it was found two consensus meFucoidan-binding motifs (B-X-B-B-X-S/T and B-B-B-B-B-S/T) to be partly overlapping to the potent phosphorylation site (B-B-X-S/T) for A-kinase (Table  1) . This assumption is supported by indirect evidence that (i) annexin II (pIϭapprox. 7.6) contains a potent phosphorylation site for A-kinase and three K/R-rich meFucoidan-binding domains; (ii) the direct binding of annexins to meFucoidan causes their conformational changes and reduces their binding abilities with phospholipids 19) ; and (iii) the similar meFucoidan-binding domains are seen in other meFucoidanbinding selectins, which mediate leukocyte adhesion by recognition of cell-specific carbohydrate ligands. 20) 716
Vol. 31, No. 4 [A] The binding affinities of bFGF and four synthetic peptides (sp5, GE13, RS6 and RS6 variant, approx. 2 mg each) were separately determined by a QCM. a, sp5; b, bFGF; c, GE-13; d, RS6; and e, RS6 variant; and f, peptide M107 (negative control).
[B] Four substrates (bFGF, sp5, GE-13 and RS6, approx. 2 mg each) were separately incubated with A-kinase in the standard reaction mixtures, containing 5 mM [g-32 P]ATP (500 cpm/pmol). After incubation for 30 min at 30°C in the presence and absence of meFucoidan or sulfatide, 32 P-labeled bFGF, sp5, GE-13 or RS6 in the reaction mixtures was detected by autoradiography after SDS-PAGE. The autoradiogram was scanned by a spectrophotometer. 100% represents the A-kinase-mediated phosphorylation of these four peptides in the absence of meFucoidan. ᭺, bFGF; ᮀ, sp5; ᭹, GE-13; and , RS6.
Cardin and Weintraub first reported the existence of two heparin-binding consensus motifs (X-B-B-B-X-B-X and X-B-B-X-B-X) in several heparin-binding proteins, including annexins and selectins. 21) These two consensus heparin-binding sequences in annexin II and L-selectin are also recognized with fucoidan, 19) and are similar to two consensus meFucoidan-binding motifs (B-B-B-B-B-S/T and B-X-B-B-X-S/T) in several functional basic substrates for A-kinase. Therefore, it is possibility to conclude that meFucoidan may function as an effective suppressor for the A-kinase-mediated phosphorylation of several meFucoidan-binding functional proteins, containing multiple phosphorylation sites for the kinase, through its direct binding to the K/R-rich domains in these basic proteins in the digestive bowels.
To clearly understand the biological mechanisms of the meFucoidan-induced anti-inflammatory and anti-allergic effects in vivo, further analytical studies are required to (i) identify novel meFucoidan-binding proteins (meF-BPs) involved in the mechanisms of inflammatory and allergic diseases after purification and characterization of novel meFBPs from the synovial fluids of patients with rheumatoid arthritis and from sera of allergic diseases using a meFucoidan-affinity column; and (ii) characterize meFucoidan as a potent suppressors for the physiological functions of meFBPs and selective inhibitor for their phosphorylation by Akinase in vitro. After the detail biochemical and biological characterization of the physiological interaction of purified novel meF-BPs with meFucoidan in vitro, it is possible to explain the biochemical mechanisms of the inflammatory and anti-allergic effects of meFucoidan in vivo, and also to propose as an effective natural medicine for inflammatory diseases and rheumatoid arthritis. Either histone H2B or Hcore 164B (approx. 2 mg each) was incubated with A-kinase in the standard reaction mixtures, containing 5 mM [g-32 P]ATP (500 cpm/pmol). After incubation for 30 min at 30°C in the presence of the indicated concentrations of meFucoidan or heparin, 32 P-labeled histone H2B [A] or Hcore 164B [B] in the reaction mixtures was detected by autoradiography after SDS-PAGE. The autoradiogram was scanned by a spectrophotometer. 100% represents the A-kinase-mediated phosphorylation of these two basic proteins in the absence of meFucoidan and heparin. ᭹, meFucoidan (1); and ᭺, heparin (2).
[C] The binding affinities of histone H2B (a) and Hcore 164B (b) with 10 mg/ml meFucoidan ( ) or 10 mg/ml heparin (------) were determined by a QCM. Poly-Arg (c) was used as a positive control for the binding affinity of meFucoidan.
